Everpar Advisors LLC Has $2.07 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Everpar Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,680 shares of the company’s stock after buying an additional 17 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of Everpar Advisors LLC’s portfolio, making the stock its 17th largest position. Everpar Advisors LLC’s holdings in Eli Lilly and Company were worth $2,069,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Beck Bode LLC bought a new position in shares of Eli Lilly and Company during the second quarter worth $15,036,000. XTX Topco Ltd acquired a new stake in Eli Lilly and Company during the 2nd quarter worth $546,000. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Eli Lilly and Company by 3.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 8,723 shares of the company’s stock valued at $7,898,000 after purchasing an additional 276 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of Eli Lilly and Company by 5.8% in the 2nd quarter. Pacer Advisors Inc. now owns 68,017 shares of the company’s stock valued at $61,581,000 after purchasing an additional 3,713 shares during the period. Finally, Garden State Investment Advisory Services LLC increased its stake in Eli Lilly and Company by 14.8% during the 2nd quarter. Garden State Investment Advisory Services LLC now owns 2,262 shares of the company’s stock worth $2,052,000 after purchasing an additional 291 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Bank of America restated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Barclays reduced their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $726.24 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $612.70 and a twelve month high of $972.53. The company has a 50-day simple moving average of $781.14 and a two-hundred day simple moving average of $854.71. The stock has a market capitalization of $689.43 billion, a price-to-earnings ratio of 78.51, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. Analysts forecast that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.